Han Hoon
Director/Board Member at The Korean Society for Biomaterials
Profile
Dr. Han Hoon is Co-Chairman at AmStem Corp., Chief Executive Officer at Histostem Co., Ltd., Representative-Korea at AsiaCORD, and a Member at Society for Hematology & Stem Cells.
He is on the Board of Directors at The Korean Society for Biomaterials.
Dr. Hoon was previously employed as Chairman by Stem Cell Therapy International, Inc.
He received his doctorate degree from the Catholic University of Korea and a doctorate degree from the Catholic University of Korea.
Han Hoon active positions
| Companies | Position | Start |
|---|---|---|
| AsiaCORD | Corporate Officer/Principal | 17/10/2011 |
| Society for Hematology & Stem Cells | Corporate Officer/Principal | 17/10/2011 |
| The Korean Society for Biomaterials | Director/Board Member | 17/10/2011 |
Former positions of Han Hoon
| Companies | Position | End |
|---|---|---|
Stem Cell Therapy International, Inc.
 Stem Cell Therapy International, Inc. Miscellaneous Commercial ServicesCommercial Services Stem Cell Therapy International, Inc. is a surgical procedure that has been used successfully for 70+ years as a treatment of many diseases for which modern medicine has had no therapy, or in which 'state-of-art' therapies stopped being effective. A documented 5 millions of patients have been so treated worldwide to-date, evidenced by over 120,000 publications in MEDLINE amongst others. SCT is approved for use by the German authorities and the EU. | Chairman | 23/02/2010 |
AmStem Corp.
 AmStem Corp. Pharmaceuticals: OtherHealth Technology AmStem Corp. researches and develops stem cell transplantation therapy and regenerative medicine. The company owns cord blood stem cell bank in Korea. The company was founded on December 28, 1992 and is headquartered in San Francisco, CA. | Chairman | - |
Hucord Co., Ltd.
 Hucord Co., Ltd. BiotechnologyHealth Technology Hucord Co., Ltd. is a biotechnology company engaged in human cell-based therapy. It develops stem cell technology along with the cord blood, specializing in Multi-Lineage Progenitor Cells (MLPCs) research, treatment of disease and banking of cells. The group works in the following divisions: cord blood banking, stem cell banking, stem cell research and development, stem cell therapy management and the immunogenetics laboratory. It also performs the Human leukocyte antigen typing method which determines the compatibility of tissues between patient and the donor. The company was founded on January 24, 1979 and is headquartered in Yongin-si, South Korea. | Chief Executive Officer | - |
Training of Han Hoon
| Catholic University of Korea | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
 | Health Technology |
| Private companies | 5 |
|---|---|
Stem Cell Therapy International, Inc.
Stem Cell Therapy International, Inc. Miscellaneous Commercial ServicesCommercial Services Stem Cell Therapy International, Inc. is a surgical procedure that has been used successfully for 70+ years as a treatment of many diseases for which modern medicine has had no therapy, or in which 'state-of-art' therapies stopped being effective. A documented 5 millions of patients have been so treated worldwide to-date, evidenced by over 120,000 publications in MEDLINE amongst others. SCT is approved for use by the German authorities and the EU. | Commercial Services |
AmStem Corp.
AmStem Corp. Pharmaceuticals: OtherHealth Technology AmStem Corp. researches and develops stem cell transplantation therapy and regenerative medicine. The company owns cord blood stem cell bank in Korea. The company was founded on December 28, 1992 and is headquartered in San Francisco, CA. | Health Technology |
| The Korean Society for Biomaterials | |
| AsiaCORD | |
| Society for Hematology & Stem Cells |
- Stock Market
- Insiders
- Han Hoon
